Manager × security

Moody Aldrich Partners LLC BBIO holdings history

Who else holds this security?

BRIDGEBIO PHARMA INC · CUSIP 10806X102 · CIK 936941

This is the oldest quarter open without an account, so changes against the quarter before it are withheld. Sign in to see them.
Citable facts

As of 2026-06-30, Moody Aldrich Partners LLC reported 3.46K BBIO (shares), valued at $257.33K, or 0.05% of its reported non-derivative portfolio. Filed 2026-07-15.

Verify history & sources
Portfolio weight and quantity history
Reported portfolio weight
0.05%
Shares
3.46K
3,455
Reported value
$257.33K
USD

Shares decreased 95.45%; reported value decreased 95.44%, and weight changed -0.97 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.

Left: % · Right: Shares · Independently scaled axes

Exact data and methodology

Axes scale independently; a crossing does not mean equal values. Weight uses each quarter's total reported non-derivative value. Same CUSIP; missing quarters are gaps, not zero. Revised history may include later disclosures.

QuarterWeightQuantitySource
Q2 20260.05%3,455SEC filingFiled Jul 15, 2026
Q1 20261.02%75,948SEC filingFiled Apr 20, 2026
Q4 20251.87%131,184SEC filingFiled Jan 30, 2026
Q3 20250.71%71,580SEC filingFiled Oct 21, 2025
Q2 20250.80%95,435SEC filingFiled Aug 4, 2025
Q1 20250.70%96,915SEC filingFiled Apr 29, 2025
Q4 20240.51%99,684SEC filingFiled Jan 23, 2025
Q3 20240.57%123,509SEC filingFiled Oct 22, 2024
Q2 20240.62%125,829SEC filingFiled Jul 24, 2024
Q1 20240.78%149,222SEC filingFiled Apr 30, 2024
Q4 20230.91%124,984SEC filingFiled Jan 26, 2024
Q3 20230.69%137,512SEC filingFiled Nov 8, 2023

History & evidence by quarter

QuarterWeightQuantityValueChange explainedSource
Q3 20230.69%137,512$3.63MThe prior quarter is outside the free window. Sign in for the comparison.SEC filing
Filed Nov 8, 2023
Q4 20230.91%124,984$5.05MShares decreased 9.11%; reported value increased 39.14%, and weight changed +0.22 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing
Filed Jan 26, 2024
Q1 20240.78%149,222$4.61MShares increased 19.39%; reported value decreased 8.56%, and weight changed -0.13 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing
Filed Apr 30, 2024
Q2 20240.62%125,829$3.19MShares decreased 15.68%; reported value decreased 30.92%, and weight changed -0.16 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing
Filed Jul 24, 2024
Q3 20240.57%123,509$3.14MShares decreased 1.84%; reported value decreased 1.34%, and weight changed -0.05 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing
Filed Oct 22, 2024
Q4 20240.51%99,684$2.74MShares decreased 19.29%; reported value decreased 13.01%, and weight changed -0.06 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing
Filed Jan 23, 2025
Q1 20250.70%96,915$3.35MShares decreased 2.78%; reported value increased 22.48%, and weight changed +0.19 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing
Filed Apr 29, 2025
Q2 20250.80%95,435$4.12MShares decreased 1.53%; reported value increased 23.00%, and weight changed +0.10 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing
Filed Aug 4, 2025
Q3 20250.71%71,580$3.72MShares decreased 25.00%; reported value decreased 9.78%, and weight changed -0.09 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing
Filed Oct 21, 2025
Q4 20251.87%131,184$10.03MShares increased 83.27%; reported value increased 169.89%, and weight changed +1.16 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing
Filed Jan 30, 2026
Q1 20261.02%75,948$5.64MShares decreased 42.11%; reported value decreased 43.79%, and weight changed -0.85 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing
Filed Apr 20, 2026
Q2 20260.05%3,455$257.33KShares decreased 95.45%; reported value decreased 95.44%, and weight changed -0.97 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing
Filed Jul 15, 2026
Moody Aldrich Partners LLC · BRIDGEBIO PHARMA INC

Take these holdings further.

This page includes 12 of 12 reported holdings. Sign in to look up the full history beyond 3 years, use advanced screening & filtering, download CSV, and get the complete set through the Akkru API.

  • Download CSV
  • Earlier quarters
  • Advanced screening & filtering
  • API & AI access
Already have an account?

New accounts get free API credits to explore data beyond ownership filings.

For AI agents & developers

The initial HTML of this page carries its exact data as script#research-data (JSON): values, units, scope, preview limits and SEC sources. Read it directly, no script or API key needed; script#research-access says what needs an account.

Without an account: the last 3 years, with the row caps stated on the page. A free account opens all history on file on these pages and the CSV of what a page shows. Rows beyond the caps and bulk retrieval go through the authenticated API / MCP.

MCP  https://api.akkrudata.ai/mcp

get_institutional_portfolio
{"cik":"936941","quarter":"2026Q2","cusip":"10806X102"}

get_institutional_manager_history
{"cik":"936941","page_size":100}

Connect to MCP with OAuth and follow the returned pagination. Credits and usage limits depend on the account.

MCP endpoint
https://api.akkrudata.ai/mcp
API / MCP documentation
/documents
llms.txt
/llms.txt
Sources, coverage & how to read this data

Figures are as reported to the SEC and merged with later amendments where Akkru could match them. Preview limits apply to what is listed, not to the totals, which come from the complete reported data. Nothing is zero-filled: a missing quarter or month is shown as missing.

13F reports quarter-end long positions in securities traded on US exchanges, filed by managers holding at least $100 million of such securities; it is not the manager's full portfolio, not assets under management, and value changes are not returns. Weights use the reported total value as denominator. Option rows show notional value, not premium or net exposure. Amendments are merged into the quarter when Akkru could match them.